Menu
Back to Journals » Patient Preference and Adherence » Volume 7
User assessment of Norditropin NordiFlex®,a new prefilled growth hormone pen:a Phase IV multicenter prospective study
Authors Tauber M, Jaquet D, Jesuran-Perelroizen M, Petrus M, Bertrand AM, Coutant R
Received 30 January 2013
Accepted for publication 15 March 2013
Published 24 May 2013 Volume 2013:7 Pages 455—462
DOI https://doi.org/10.2147/PPA.S43460
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Maithé Tauber,1 Delphine Jaquet,2 Monique Jesuran-Perelroizen,3 Marc Petrus,4 Anne Marie Bertrand,5 Regis Coutant6
NordiFlex® French Study Group
1Hôpital des Enfants, Toulouse, 2Novo Nordisk, La Défense Cédex, 3Cabinet d’Endocrinologie Pédiatrique, Toulouse, 4Centre Hospitalier de Bigorre, Tarbes, 5Centre Hospitalier Universitaire de Besançon, Besançon, 6Centre Hospitalier Universitaire Angers, Angers, France
Background/aim: In growth disorders, ensuring long-term growth hormone therapy (GHT) remains a challenge that might compromise the clinical outcome. Consequently, strategies aiming at alleviating the burden of daily injection might improve the treatment benefit. The study reported here was performed to assess the ease of use of Norditropin NordiFlex® (Novo Nordisk, Princeton, NJ, USA) compared with that of the devices previously used in children treated with GHT with recombinant somatropin.
Methods: This Phase IV prospective, multicenter, open-label study was conducted in France. All patients received Norditropin NordiFlex for 6 weeks. Oral questionnaires were administered by the physician to the patients and/or the parents at inclusion and at the final visit.
Results: This study included 103 patients aged between 6 and 17 years. The patients assessed Norditropin NordiFlex as significantly easier to use than their previous device (median value = 7.5, P < 0.001). Almost three-quarters of patients (64.4%) preferred Norditropin NordiFlex to their previous device. Among physicians and nurses, 73% assessed Norditropin NordiFlex training as "very easy" and 26% as "easy." Norditropin NordiFlex improved patient autonomy, with 41% of patients able to self-inject the treatment.
Conclusion: This study has shown that Norditropin NordiFlex is reliable, safe, and easy to use and most study patients preferred it to their previous device. These characteristics may improve the adherence to GHT.
Keywords: growth hormone therapy, adherence, injection devices, preference, ease of use
Corrigendum for this paper has been published
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.